World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
59
Citations
14365
World Ranking
3411
National Ranking
88

Overview

Laszlo Radvanyi is affiliated with the Ontario Institute for Cancer Research in Canada. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, Medicine, and Immunology and Microbiology. Within these main fields, their work is concentrated in the subfields of Immunology, Molecular Biology, Oncology, Cancer Research, and Economics and Econometrics.

Their research topics include:

  • Extracellular vesicles in disease
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer-related molecular mechanisms research
  • Health Systems, Economic Evaluations, Quality of Life

Recent papers authored or co-authored by Laszlo Radvanyi include:

  • Germline genetic contribution to the immune landscape of cancer, 2021, Immunity
  • Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma, 2022, Cancers
  • Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma, 2021, Journal for ImmunoTherapy of Cancer
  • VISTA expression and patient selection for immune-based anticancer therapy, 2023, Frontiers in Immunology
  • Germline genetic contribution to the immune landscape of cancer, 2020, bioRxiv (Cold Spring Harbor Laboratory)

Frequent co-authors collaborating with Laszlo Radvanyi are:

  • Valentina Evdokimova
  • Hendrik Gassmann
  • Lincoln Stein
  • Stefan Burdach
  • Peter Ruzanov

The scientist has published multiple articles in recognized journals, with notable frequent venues including:

  • Frontiers in Immunology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Immunity
  • Cancers

Best Publications

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • PD-L1 expression and prognostic impact in glioblastoma.

    Edjah K. Nduom;Jun Wei;Nasser K. Yaghi;Neal Huang

  • Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

    Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad

  • PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

    Weiyi Peng;Chengwen Liu;Chunyu Xu;Yanyan Lou

  • Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

    Laszlo G. Radvanyi;Chantale Bernatchez;Minying Zhang;Patricia S. Fox

  • Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

    Yan Lan;Dong Zhang;Chunxiao Xu;Kenneth W. Hance

  • Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3

    Hiroshi Nishina;Klaus D. Fischer;Klaus D. Fischer;Laszlo Radvanyi;Arda Shahinian

  • BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

    Chengwen Liu;Weiyi Peng;Chunyu Xu;Yanyan Lou

  • Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

    Jahan S. Khalili;Shujuan Liu;Tania G. Rodríguez-Cruz;Mayra Whittington

  • Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

    Young Hee Lee;Natalia Martin-Orozco;Natalia Martin-Orozco;Peilin Zheng;Jing Li

  • The IL-2 cytokine family in cancer immunotherapy

    Geok Choo Sim;Laszlo Radvanyi

  • Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

    Richard Wu;Marie Andrée Forget;Jessica Chacon;Jessica Chacon;Chantale Bernatchez

  • IL-2 therapy promotes suppressive ICOS + Treg expansion in melanoma patients

    Geok Choo Sim;Natalia Martin-Orozco;Lei Jin;Yan Yang

  • Rapamycin Enhances Apoptosis and Increases Sensitivity to Cisplatin in Vitro

    Yufang Shi;Andrea Frankel;Laszlo G. Radvanyi;Linda Z. Penn

  • The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer

    Laszlo Radvanyi;Devender Singh-Sandhu;Scott Gallichan;Corey Lovitt

  • CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response

    Laszlo G. Radvanyi;Yufang Shi;Homayoun Vaziri;Ajay Sharma

  • Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers

    Giampaolo Bianchini;Yuan Qi;Ricardo H. Alvarez;Takayuki Iwamoto

  • Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.

    Feng Wang-Johanning;Laszlo Radvanyi;Kiera Rycaj;Joshua B. Plummer

  • Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling

    Lorenzo Cohen;Steven W. Cole;Anil K. Sood;Sarah Prinsloo

  • Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death

    L. G. Radvanyi;Gordon B Mills;R. G. Miller

Frequent Co-Authors

Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center
Cara Haymaker
Cara Haymaker The University of Texas MD Anderson Cancer Center
Willem W. Overwijk
Willem W. Overwijk The University of Texas MD Anderson Cancer Center
Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center
Jason Roszik
Jason Roszik The University of Texas MD Anderson Cancer Center
Gordon B. Mills
Gordon B. Mills Oregon Health & Science University
Richard G. Miller
Richard G. Miller University of Toronto
Jeffrey E. Gershenwald
Jeffrey E. Gershenwald The University of Texas MD Anderson Cancer Center
Laurence J.N. Cooper
Laurence J.N. Cooper The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related nursing and healthcare degrees can expand career opportunities. Many professionals consider bridging their skills through programs like the fnp to acute care np bridge program to specialize further in patient care with advanced roles.

Accelerated nursing programs offer a fast track for students from non-nursing backgrounds. For example, the accelerated fnp programs allow candidates to become Family Nurse Practitioners more quickly, integrating care skills that complement immunology knowledge.

Similarly, those without prior nursing experience can begin with the best online rn programs for non nurses. These programs provide foundational clinical training and licensure, opening the door to various healthcare professions linked to immunology research and practice.

Lastly, beginners aiming to enter the nursing field might explore the accelerated nursing programs designed for faster admission and completion. These adaptable pathways facilitate quick entry into healthcare roles where immunology expertise is an asset.

Best Scientists Citing Laszlo Radvanyi

Trending Scientists